Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing Vaccine

Study Overview
=================
Brief Summary
-----------------
This study was aimed to conduct a 3-year perspective study to observe the immunological effect of one-dose mumps-containing vaccine, monitor the incidence of mumps in vaccinated population aged 3-7 years，and provide basis for adjusting MMR immunization strategy in Jiangsu province, China.

Detailed Description
-----------------
in 3-7 years old children with high risk of mumps, epidemiological investigation of the serum IgG antibody level were conducted, and then a prospective observational cohort was established in the population with a history of mumps vaccination, and the incidence of mumps in each antibody level group will be observed, the relationship between different antibody levels and the incidence after mumps vaccinated were analyzed, to explore attenuation of mumps IgG antibody levels in the body,S79 vaccine strain against F genotype mumps' antigenic cross-reactivity and the protective effect of antibodies.

Official Title
-----------------
Observational Cohort Study to Evaluate Immunogenicity, Protection, and Persistence of Antibody to Mumps in 3-7 Years' Children Received One-dose Mumps-containing Vaccine

Conditions
-----------------
Parotid Gland Infection, Fever

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children aged 3-7 years old; local resident children living at least 3 months; physical health, has been vaccinated at least once a dose of MuV Exclusion Criteria: did not administer MuV; refused to collect venous blood; have been infected with mumps; have serious illness or other reasons should not participate in the study after clinical evaluation

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GMT-low-level group<br>low geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study | |
| GMT-high-level group<br>high geometric mean titer (GMT) detected in the children who had received one-dose mumps-containing vaccine from precious cross sectional study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to describe the sero-prevalence in specific age groups following an active surveillance of vaccinated subjects in each year |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to describe wane immunity of IgG antibody to mumps virus in specific age groups following an active surveillance of vaccinated subjects in each year |  | 3 years | 
| To characterize the incidence of mumps in specific age groups following an active surveillance of vaccinated subjects in each year |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mumps, immunity, cohort study, children, vaccine